RECRUITING Phase 1 ClinicalTrials.gov

A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Sponsor: Genentech, Inc. • ClinicalTrials.gov ID: NCT07558915

Registry updated: 2026-10-09

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This study will evaluate safety, pharmacokinetics (PK), clinical activity and pharmacodynamics (PD) of RO7851624 in participants with RRMM who are triple-class exposed (treated with proteasome inhibitors \[PIs\], immunomodulators \[IMiDs\], and anti-cluster of differentiation 38 \[anti-CD38\] monoclonal antibodies), and have limited remaining standard treatment options due to refractoriness, intolerance, or multiple prior therapies.

Interventions

RO7851624 (Drug)
Participants will receive RO7851624 as per the schedule described in the protocol.

Eligibility criteria

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Life expectancy of at least 12 weeks. * Diagnosis of multiple myeloma per International Myeloma Working Group (IMWG) criteria. * Measurable disease. Exclusion Criteria: * Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) with insufficient washout prior to ﬁrst dose of study treatment. * Autologous stem cell transplant (SCT) with insufficient time prior to ﬁrst dose of study treatment. * Prior allogeneic SCT. * Prior solid organ transplantation.

Conditions

Relapsed/Refractory Multiple Myeloma

Locations

Peter MacCallum Cancer Center — Parkville, Victoria, Australia

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment